M Bonnet1, M Bastard2, P du Cros3, A Khamraev4, K Kimenye5, S Khurkhumal6, A Hayrapetyan7, D Themba8, A Telnov9, E Sanchez-Padilla2, C Hewison10, F Varaine10. 1. Epicentre, Paris, France; Institut de Recherche pour le Développement UMI 233 TransVIHMI - UM - INSERM U117, Montpellier, France. 2. Epicentre, Paris, France. 3. Médecins Sans Frontières (MSF), London, UK. 4. Ministry of Health of Karakalpakstan, Nukus, Uzbekistan. 5. Division of Leprosy Tuberculosis and Lung Disease, Nairobi, Kenya. 6. Abkhazian National Tuberculosis Programme, Sukhumi, Abkhazia. 7. Armenian National Tuberculosis Programme, Yerevan, Armenia. 8. Ministry of Health of Swaziland, Mbabane, Swaziland. 9. MSF, Geneva, Switzerland. 10. MSF, Paris, France.
Abstract
BACKGROUND: The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome. OBJECTIVE: To identify patients at risk of unfavourable outcomes who may benefit from the new drugs. METHODS: Retrospective cohort study of treatment outcomes involving four to five effective drugs for 15-24 months in programmes in Uzbekistan, Georgia, Armenia, Swaziland and Kenya between 2001 and 2011. RESULTS: Of 1433 patients, 48.5% had body mass index (BMI) <18.5 kg/m(2), 72.9% had a high bacillary load, 16.7% were resistant to two injectables, 2.9% were resistant to ofloxacin (OFX) and 3.0% had extensively drug-resistant TB (XDR-TB). Treatment success ranged from 59.7% (no second-line resistance) to 27.0% (XDR-TB). XDR-TB (aOR 8.16, 95%CI 3.22-20.64), resistance to two injectables (aOR 1.90, 95%CI 1.00-3.62) or OFX (aOR 5.56, 95%CI 2.15-14.37), past incarceration (aOR 1.88, 95%CI 1.11-3.2), history of second-line treatment (aOR 3.24, 95%CI 1.53-6.85), low BMI (aOR 2.22, 95%CI 1.56-3.12) and high bacillary load (aOR 2.32, 95%CI 1.15-4.67) were associated with unfavourable outcomes. Patients started on capreomycin rather than kanamycin were more likely to have an unfavourable outcome (aOR 1.54, 95%CI 1.04-2.28). CONCLUSION: In our cohort, patients who may benefit from bedaquiline and delamanid represented up to two thirds of all MDR-TB patients.
BACKGROUND: The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome. OBJECTIVE: To identify patients at risk of unfavourable outcomes who may benefit from the new drugs. METHODS: Retrospective cohort study of treatment outcomes involving four to five effective drugs for 15-24 months in programmes in Uzbekistan, Georgia, Armenia, Swaziland and Kenya between 2001 and 2011. RESULTS: Of 1433 patients, 48.5% had body mass index (BMI) <18.5 kg/m(2), 72.9% had a high bacillary load, 16.7% were resistant to two injectables, 2.9% were resistant to ofloxacin (OFX) and 3.0% had extensively drug-resistant TB (XDR-TB). Treatment success ranged from 59.7% (no second-line resistance) to 27.0% (XDR-TB). XDR-TB (aOR 8.16, 95%CI 3.22-20.64), resistance to two injectables (aOR 1.90, 95%CI 1.00-3.62) or OFX (aOR 5.56, 95%CI 2.15-14.37), past incarceration (aOR 1.88, 95%CI 1.11-3.2), history of second-line treatment (aOR 3.24, 95%CI 1.53-6.85), low BMI (aOR 2.22, 95%CI 1.56-3.12) and high bacillary load (aOR 2.32, 95%CI 1.15-4.67) were associated with unfavourable outcomes. Patients started on capreomycin rather than kanamycin were more likely to have an unfavourable outcome (aOR 1.54, 95%CI 1.04-2.28). CONCLUSION: In our cohort, patients who may benefit from bedaquiline and delamanid represented up to two thirds of all MDR-TBpatients.
Authors: L Guglielmetti; C Hewison; Z Avaliani; J Hughes; N Kiria; N Lomtadze; N Ndjeka; S Setkina; A Shabangu; W Sikhondze; A Skrahina; N Veziris; J Furin Journal: Int J Tuberc Lung Dis Date: 2017-02-01 Impact factor: 2.373
Authors: C A Rodriguez; M B Brooks; L Guglielmetti; C Hewison; M F Jachym; E Lessem; F Varaine; C D Mitnick Journal: Public Health Action Date: 2019-03-21
Authors: M Taune; P Ustero; S Hiashiri; K Huang; P Aia; L Morris; S Main; G Chan; P du Cros; S S Majumdar Journal: Public Health Action Date: 2019-09-21
Authors: Jay Achar; Cathy Hewison; Ana P Cavalheiro; Alena Skrahina; Junia Cajazeiro; Parpieva Nargiza; Krzysztof Herboczek; Assliddin S Rajabov; Jennifer Hughes; Gabriella Ferlazzo; James A Seddon; Philipp du Cros Journal: Emerg Infect Dis Date: 2017-10-17 Impact factor: 6.883
Authors: D Vambe; T Dlamini; J Furin; C Gracia-Edwards; K Keus; K Kunene; A Shabangu; S N Dlamini; W Sikhondze Journal: Public Health Action Date: 2017-09-21
Authors: Marina Tadolini; Anthony J Garcia-Prats; Lia D'Ambrosio; Catherine Hewison; Rosella Centis; H Simon Schaaf; Ben J Marais; Hannetjie Ferreira; Jose A Caminero; Sylvie Jonckheere; Animesh Sinha; Krzysztof Herboczek; Zarema Khaidarkhanova; Armen Hayrapetyan; Naira Khachatryan; Ia Urtkmelidze; Carolina Loreti; Susanna Esposito; Alberto Matteelli; Jennifer Furin; Francis Varaine; Giovanni Battista Migliori Journal: Eur Respir J Date: 2016-06-23 Impact factor: 16.671